Pharmaceutical Supply, Pharmaceutical Manufacturing, Contract …
WEBPharmaceutical Supply, Pharmaceutical Manufacturing, Contract Research, Pharmaceutical Outsourcing. News and analysis on clinical trial services and contract research and development. Pfizer withdraws sickle cell disease drug Oxbryta amid safety concerns. The US big pharma company Pfizer has voluntarily withdrawn the oral sickle cell disease ...
Premier Research: holistic approach benefits development
WEBOct 6, 2020 · Holistic design starts off with designing a target product profile that considers the end goal early in the development planning. Also, part of a successful holistic approach, Sharif suggested, is asking thoughtful, appropriate questions at the outset, making sure to consider outcome-focused impactful issues at every stage of development.
Lonza opens early-phase development, manufacturing facility
WEBJun 14, 2022 · The company has completed its early-phase development and manufacturing facility in Bend, giving it 11 processing suites focused on first steps into the clinic. Switzerland-based Lonza gained a presence in Bend through its 2016 takeover of Capsugel, which had itself picked up the Oregon site in its acquisition of Bend Research a few years earlier.
Specialized CRO ‘fills the gap’ for rare disease research
WEBFeb 28, 2022 · Orphan Reach tries to fill the gap between the traditional global CRO, mostly focused on managing larger trials in common diseases, and the needs of companies that develop rare disease treatments for only a few patients. We have been operating on a global scale in more than 70 countries pretty much from …
DFE Pharma, Harro Höfliger, and Sterling forge partnership
WEBApr 6, 2022 · A trio of companies—excipients provider DFE Pharma, equipment supplier Harro Höfliger, and active pharmaceutical ingredient (API) manufacturer Sterling—have forged a partnership intended to advance dry-powder inhalation (DPI) solutions. Named Inhalation Together (INTO), the collaboration will strive to formulate respiratory treatments.
Roquette plans to open doors of new US innovation center
WEBDec 8, 2021 · Roquette, an excipients and ingredients company based in France, has announced plans to open a new Innovation Center in Pennsylvania. The company already has established centers in Singapore and France, all aimed at advancing drug delivery and helping increase speed to market. Outsourcing-Pharma recently connected with Paul Smaltz, head of ...
Afrezza approval: Validation for Mannkind's drug and delivery tech
WEBJul 1, 2014 · The US Food and Drug Administration (FDA) cleared Afrezza on June 27 in a decision that was in keeping with the recommendation issued by its Endrocinologic and Metabolic Drug Advisory Committee in April. The approval – which covers use of Afrezza as a fast-acting insulin at meal times for those with Type 1 and Type 2 diabetes – prompted a surge in Mannkind’s share price and much ...
Cloud lab solution empowers access of research tech from miles …
WEBAug 26, 2021 · Cloud lab solution empowers access of research tech from miles away. News and analysis on clinical trial services and contract research and development. Emerald Cloud Lab’s remote, automated laboratory technology puts pieces of advanced scientific equipment within the reach of smaller research outfits. Depending on the scope and complexity of ...
Memorial Hermann expands life-changing cancer care partnership
WEBSep 3, 2024 · The partnership initially launched at Memorial Hermann-Texas Medical Center, the system’s flagship hospital, with the goal of providing cancer patients with continuous, personalized care. Patients enrolled in the program have access to a team of clinical oncology specialists around the clock, with support available via …
Pfizer: collaboration key to clinical care
WEBNov 18, 2020 · Pfizer participates in many public and private partnerships. Pfizer is a key stakeholder in the creation of many of these opportunities and encourages the research community to collaborate with all stakeholders, including those practicing clinical care. OSP: What lessons has Pfizer learned from your collaborations with academics, the patient ...